Preclinical Evaluation of Potential CRS & Efficacy of Bispecific Antibodies in PBMC-Humanized Mice

June 1, 2020

Jing Jiao, Ph.D. Presents "Preclinical Evaluation of Potential Cytokine Release Syndrome and Efficacy of Bispecific Antibodies in PBMC-Humanized Mice"

Preclinical Evaluation of Potential CRS & Efficacy of Bispecific Antibodies in PBMC-Humanized Mice

JAX Humanized Mice PubCast: Mast cells & Anti-PD-1 Therapy (Apr. 3, 2024)

JAX Humanized Mice PubCast: HIV-1 in Humanized Mice (Mar. 14, 2024)

Comparing Immune-Humanized Mouse Platforms for Preclinical Applications

Comparing Immunodeficient Models for Cancer, Immunity, and Transplant Research

Translatable Efficacy & Safety Testing of mAb, Bispecific, & CAR T Therapies

De-Risk Therapeutic Antibody Drug Development Using Humanized FcRn Platforms (Oct. 24, 2023)

New Immune-humanized Models Support More Diverse Human Immune Cell Lineages

Rapid In Vivo Evaluation of Immuno-Modulatory Therapies Using Hu-PBMC NSG™ Mice

Leveraging Gene Therapy to Achieve Long-Term Continuous or Controllable Expression of Biotherapeutics

DROSHA but not DICER is Required for Human Haematopoietic Stem Cell Function

Novel Humanized Mouse Model for Assessment of Human Allogeneic Responses in Organ Transplantation

Modeling Human Melanoma To Understand And Treat Resistance To Immunotherapy

Immune-Humanized PDX Model-Estrogen-Independent, Hormone Receptor-Positive Metastatic Breast Cancer

JAX Tech Episode 55: Let’s Talk of Mice and Monkeys (May 17, 2022)

How To Make Your New NSG Variant in a Fraction of the Time

A Novel Clinically Relevant Graft-Versus-Leukemia Model in Humanized Mice

Achieving Relevant Preclinical Characterization of CAR T Cell Therapies

2022 AACR POSTER: Enhanced Development Of Functional Human Innate Immune Cells In A Novel FLT3NullNSG Mouse Strain Expressing Human FLT3L

A MHC Class I & II Deficient Platform Humanized with PBMCs

CRS Studies for CAR T Cell Therapy